GlassScriptPhysician profile
Henry J Fishman
NPI 1295899979
$18,855.92
in general payments reported to CMS, 2019-2025
40 companies · $3,779 in 2025
The $3,779 reported for 2025 was more than what 83% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $3,982 · 2021: $1,759 · 2022: $2,082 · 2023: $2,373 · 2024: $3,199 · 2025: $3,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,351.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,014.80 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $4,763.87 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,940.77 | 2019-2025 | |
| Genentech USA, INC. | $966.22 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $938.17 | 2019-2025 | |
| Pfizer INC. | $896.74 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $641.00 | 2019-2025 | Dupixent |
| Amgen INC. | $637.95 | 2022-2025 | Tezspire |
| Kaleo, INC. | $408.49 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $365.15 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.50 | 2019-2022 | |
| Leo Pharma INC. | $182.96 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $173.80 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $155.08 | 2023-2025 | Cuvitru, Takhzyro |
| Alk-Abello, INC | $154.84 | 2020-2025 | Odactra, Ragwitek, Grastek |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.